The spread of COVID-19 showed that the ability to quickly roll out a vaccine can be a very profitable business. However, it can also be a pretty tough business. Moderna (MRNA) recently reported that it swung to a loss, and reported huge write-downs on unused supplies of its coronavirus shot.
Nevertheless, one company - GSK PLC (GSK) - is pinning its hopes for medium-term growth on vaccines for other viruses. Let’s take a closer look at GSK, which is much more than just a vaccines company.
